Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 15/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731625 | 0.76 | ATM (0.56) | — | |
| SCHEMBL28236159 | 0.75 | CYP11B2 (0.63) | CYP11B2CYP11B1RPS6KB1ROCK1 | |
| SCHEMBL732846 | 0.75 | ESR1 (0.54) | RPS6KB1ROCK1 | |
| SCHEMBL6161817 | 0.72 | CYP11B2 (0.60) | CYP11B2CYP11B1RPS6KB1ROCK1 | |
| SCHEMBL693970 | 0.72 | ALDH1A1 (0.57) | RPS6KB1ROCK1 | |
| Hydrochloric Acid SCHEMBL4923120 | 0.71 | CYP11B2 (0.59) | CYP11B2CYP11B1RPS6KB1ROCK1 | |
| SCHEMBL6259696 | 0.70 | KDM4E (0.40) | — | |
| SCHEMBL7048551 | 0.70 | KDM4E (0.37) | — | |
| SCHEMBL6161378 | 0.70 | DRD4 (0.55) | CYP11B2 | |
| SCHEMBL17896588 | 0.69 | CYP11B2 (1.00) | CYP11B2CYP11B1HTR2BHTR6RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120569-B1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8138197-B2 | Spirochromanon derivatives | MSD K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| EP-2120569-A2 | SPIROCHROMANON DERIVATIVES | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| WO-2008088692-A2 | SPIROCHROMANON DERIVATIVES | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | AKR1C3, CBR3, AKR1C4 | CYP11B2 178/4885CYP11B1 106/4885HTR2B 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.